UHS
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Universal Health Services, Inc.
- Nom
- Universal Health Services, Inc.
- Secteur
- Healthcare
- Industrie
- Medical - Care Facilities
- Bourse
- NYSE
- Capitalisation
- $11.0B
- Employés
- 101,500
- PDG
- Marc D. Miller
- Site web
- https://uhs.com
- Marché
- ACHCARDTCHECYHFMSFSNUY
Universal Health Services, Inc. (UHS), operating through its various divisions, is a healthcare entity that both owns and manages a network of acute care hospitals, along with outpatient and specialized behavioral health treatment centers. Its business operations are strategically bifurcated into two main segments: Acute Care Hospital Services and Behavioral Health Care Services. The hospitals under its management provide a comprehensive spectrum of medical provisions, encompassing general and specialty surgical interventions, internal medicine, obstetrics, urgent and emergency department services, diagnostic imaging (radiology), cancer therapy (oncology), advanced diagnostic procedures, cardiac care, pediatric medicine, pharmaceutical services, and mental health support. As of a reported date of February 24, 2022, the company's significant presence included the ownership or operation of 363 inpatient facilities, complemented by 40 outpatient and other specialized sites. These facilities are distributed across 39 U.S. states, the District of Columbia, the United Kingdom, and Puerto Rico. Beyond direct patient care, UHS also extends into commercial health insurance provision and offers a variety of crucial management support functions. These include centralized procurement, information technology infrastructure, financial oversight and control mechanisms, strategic facilities planning, physician talent acquisition, administrative staff management, marketing initiatives, and public relations efforts. Universal Health Services, Inc. was established in 1978 and maintains its principal executive offices in King of Prussia, Pennsylvania.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2023-03-24 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2019-02-26 | Elizabeth Pannill Fletcher | Sale (Full) | $1,001 - $15,000 |
| 2018-12-17 | David McKinley | Sale (Full) | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
UHS shows solid fundamental trends with improving margins and profitability (scores 65/75), but the event-driven catalyst is exceptionally weak — a single isolated congressional purchase with low conviction (0.35) and…
The first sentence of the analysis written for UHS on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.05 · operating margin 11%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 90.4% | 90.0% | 89.3% | 89.0% | 88.7% | |
| Ebit Margin | 12.2% | 10.6% | 8.0% | 7.4% | 10.9% | |
| Ebitda Margin | 15.8% | 14.3% | 12.0% | 11.8% | 15.1% | |
| Operating Profit Margin | 11.5% | 10.6% | 8.2% | 7.5% | 10.8% | |
| Pretax Profit Margin | 11.4% | 9.5% | 6.6% | 6.5% | 10.2% | |
| Continuous Operations Profit Margin | 8.7% | 7.3% | 5.0% | 4.9% | 7.8% | |
| Net Profit Margin | 8.6% | 7.2% | 5.0% | 5.0% | 7.8% | |
| Bottom Line Profit Margin | 8.6% | 7.2% | 5.0% | 5.0% | 7.8% | |
| Current Ratio | 1.052 | 1.274 | 1.396 | 1.325 | 1.141 | |
| Quick Ratio | 0.980 | 1.174 | 1.289 | 1.211 | 1.037 | |
| Solvency Ratio | 0.247 | 0.224 | 0.166 | 0.167 | 0.221 | |
| Cash Ratio | 0.043 | 0.057 | 0.059 | 0.054 | 0.058 | |
| Price To Earnings Ratio | 9.309 | 10.456 | 14.729 | 15.264 | 10.814 | |
| Price To Earnings Growth Ratio | 0.255 | 0.159 | 1.214 | -0.663 | 1.286 | |
| Forward Price To Earnings Growth Ratio | 0.255 | 0.159 | 1.214 | -0.663 | 1.286 | |
| Price To Earnings Diluted Ratio | 9.438 | 10.667 | 14.901 | 15.415 | 10.970 | |
| Price To Earnings Diluted Growth Ratio | 0.253 | 0.166 | 1.250 | -0.680 | 1.452 | |
| Price To Book Ratio | 1.905 | 1.791 | 1.719 | 1.740 | 1.757 | |
| Price To Sales Ratio | 0.798 | 0.754 | 0.740 | 0.769 | 0.846 | |
| Price To Free Cash Flow Ratio | 16.323 | 10.630 | 20.138 | 39.316 | 381.631 | |
| Price To Operating Cash Flow Ratio | 7.435 | 5.777 | 8.335 | 10.343 | 12.108 | |
| Debt To Assets Ratio | 0.345 | 0.342 | 0.384 | 0.391 | 0.348 | |
| Debt To Equity Ratio | 0.757 | 0.743 | 0.873 | 0.890 | 0.749 | |
| Debt To Capital Ratio | 0.431 | 0.426 | 0.466 | 0.471 | 0.428 | |
| Long Term Debt To Capital Ratio | 0.369 | 0.401 | 0.438 | 0.444 | 0.405 | |
| Financial Leverage Ratio | 2.193 | 2.171 | 2.272 | 2.279 | 2.150 | |
| Working Capital Turnover Ratio | 44.859 | 22.549 | 20.102 | 29.698 | 23.405 | |
| Operating Cash Flow Ratio | 0.576 | 0.935 | 0.630 | 0.520 | 0.445 | |
| Operating Cash Flow Sales Ratio | 0.107 | 0.131 | 0.089 | 0.074 | 0.070 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.456 | 0.543 | 0.414 | 0.263 | 0.032 | |
| Debt Service Coverage Ratio | 2.332 | 8.482 | 4.474 | 6.544 | 12.003 | |
| Interest Coverage Ratio | 12.680 | 8.968 | 5.671 | 7.885 | 15.986 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.270 | 51.601 | 10.007 | 12.229 | 18.255 | |
| Operating Cash Flow Coverage Ratio | 0.339 | 0.417 | 0.236 | 0.189 | 0.194 | |
| Capital Expenditure Coverage Ratio | 1.837 | 2.190 | 1.706 | 1.357 | 1.033 | |
| Dividend Paid And Capex Coverage Ratio | 1.748 | 2.073 | 1.588 | 1.257 | 0.959 | |
| Dividend Payout Ratio | 0.034 | 0.047 | 0.077 | 0.087 | 0.066 | |
| Enterprise Value Multiple | 7.011 | 7.403 | 9.221 | 9.822 | 7.928 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 90.5% | ▲0.5% | ▲1.0% |
| Ebit Margin | 12.2% | ▲1.6% | ▲2.4% |
| Ebitda Margin | 15.8% | ▲1.5% | ▲2.0% |
| Operating Profit Margin | 11.5% | ▲0.9% | ▲1.8% |
| Pretax Profit Margin | 11.4% | ▲1.9% | ▲2.5% |
| Continuous Operations Profit Margin | 8.7% | ▲1.4% | ▲1.9% |
| Net Profit Margin | 8.6% | ▲1.4% | ▲1.8% |
| Bottom Line Profit Margin | 8.6% | ▲1.4% | ▲1.8% |
| Current Ratio | 1.052 | ▼-0.222 | ▼-0.186 |
| Quick Ratio | 0.980 | ▼-0.194 | ▼-0.158 |
| Solvency Ratio | 0.247 | ▲0.022 | ▲0.042 |
| Cash Ratio | 0.043 | ▼-0.015 | ▼-0.012 |
| Price To Earnings Ratio | 9.309 | ▼-1.147 | ▼-2.805 |
| Price To Earnings Growth Ratio | 0.255 | ▲0.096 | ▼-0.195 |
| Forward Price To Earnings Growth Ratio | 0.255 | ▲0.096 | ▼-0.195 |
| Price To Earnings Diluted Ratio | 9.438 | ▼-1.229 | ▼-2.840 |
| Price To Earnings Diluted Growth Ratio | 0.253 | ▲0.087 | ▼-0.235 |
| Price To Book Ratio | 1.905 | ▲0.114 | ▲0.123 |
| Price To Sales Ratio | 0.798 | ▲0.044 | ▲0.017 |
| Price To Free Cash Flow Ratio | 16.323 | ▲5.692 | ▼-77.285 |
| Price To Operating Cash Flow Ratio | 7.435 | ▲1.658 | ▼-1.364 |
| Debt To Assets Ratio | 0.345 | ▲0.003 | ▼-0.017 |
| Debt To Equity Ratio | 0.757 | ▲0.014 | ▼-0.045 |
| Debt To Capital Ratio | 0.431 | ▲0.004 | ▼-0.014 |
| Long Term Debt To Capital Ratio | 0.369 | ▼-0.032 | ▼-0.042 |
| Financial Leverage Ratio | 2.193 | ▲0.023 | ▼-0.020 |
| Working Capital Turnover Ratio | 44.859 | ▲22.310 | ▲16.736 |
| Operating Cash Flow Ratio | 0.576 | ▼-0.360 | ▼-0.046 |
| Operating Cash Flow Sales Ratio | 0.107 | ▼-0.023 | ▲0.013 |
| Free Cash Flow Operating Cash Flow Ratio | 0.456 | ▼-0.088 | ▲0.114 |
| Debt Service Coverage Ratio | 2.332 | ▼-6.150 | ▼-4.435 |
| Interest Coverage Ratio | 12.680 | ▲3.712 | ▲2.442 |
| Short Term Operating Cash Flow Coverage Ratio | 2.270 | ▼-49.332 | ▼-16.603 |
| Operating Cash Flow Coverage Ratio | 0.339 | ▼-0.079 | ▲0.064 |
| Capital Expenditure Coverage Ratio | 1.837 | ▼-0.354 | ▲0.212 |
| Dividend Paid And Capex Coverage Ratio | 1.748 | ▼-0.325 | ▲0.223 |
| Dividend Payout Ratio | 0.034 | ▼-0.012 | ▼-0.028 |
| Enterprise Value Multiple | 7.011 | ▼-0.393 | ▼-1.266 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $13.86B | $11.94B | $10.57B | $10.30B | $10.70B | |
| Enterprise value | $19.23B | $16.77B | $15.81B | $15.47B | $15.14B | |
| EV / Sales | 1.11x | 1.06x | 1.11x | 1.16x | 1.20x | |
| EV / Op. cash flow | 10.31x | 8.11x | 12.47x | 15.53x | 17.14x | |
| EV / Free cash flow | 22.64x | 14.93x | 30.14x | 59.04x | 540.14x | |
| EV / EBITDA | 7.01x | 7.40x | 9.22x | 9.82x | 7.93x | |
| Net debt / EBITDA | 1.96x | 2.13x | 3.06x | 3.28x | 2.33x | |
| Current ratio | 1.05x | 1.27x | 1.40x | 1.32x | 1.14x | |
| Income quality | 1.23x | 1.78x | 1.77x | 1.52x | 0.90x | |
| Graham number | $246 | $197 | $144 | $130 | $141 | |
| Graham net-net | -$100 | -$88 | -$85 | -$79 | -$65 | |
| Tax burden | 75.5% | 76.2% | 76.3% | 78.0% | 76.7% | |
| Interest burden | 92.8% | 89.1% | 82.0% | 87.2% | 93.9% | |
| Working capital | $168.3M | $605.9M | $798.0M | $622.9M | $279.4M | |
| Invested capital | $11.62B | $11.61B | $11.29B | $10.91B | $10.48B | |
| Return on assets | 9.3% | 7.9% | 5.1% | 5.0% | 7.6% | |
| Operating ROA | 13.1% | 11.8% | 8.6% | 7.5% | 10.3% | |
| Return on tangible assets | 12.5% | 10.9% | 7.2% | 7.0% | 10.9% | |
| Return on equity | 20.5% | 17.1% | 11.7% | 11.4% | 16.3% | |
| Return on invested capital | 11.3% | 10.6% | 7.4% | 6.5% | 9.3% | |
| Return on capital employed | 15.7% | 13.7% | 9.8% | 8.7% | 12.3% | |
| Earnings yield | 10.7% | 9.6% | 6.8% | 6.6% | 9.3% | |
| Free cash flow yield | 6.1% | 9.4% | 5.0% | 2.5% | 0.3% | |
| Capex / Op. cash flow | 54.4% | 45.7% | 58.6% | 73.7% | 96.8% | |
| Capex / Depreciation | 164.1% | 161.4% | 130.8% | 126.1% | 160.5% | |
| Capex / Sales | 5.8% | 6.0% | 5.2% | 5.5% | 6.8% | |
| SG&A / Sales | 47.4% | 48.4% | 50.8% | 51.4% | 49.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.6% | 0.6% | 0.6% | 0.6% | 0.6% | |
| Intangibles / Total assets | 25.5% | 27.7% | 28.2% | 29.0% | 30.3% | |
| Days sales outstanding | 55d | 50d | 57d | 55d | 50d | |
| Days payables outstanding | 165d | 145d | 146d | 158d | 169d | |
| Operating cycle | 106d | 101d | 109d | 109d | 103d | |
| Cash conversion cycle | -59d | -44d | -37d | -49d | -65d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Universal Health Services, Inc. Announces Date for Third Quarter 2026 Earnings Release and Conference Call Universal Health Services, Inc. (NYSE: UHS) announced it will report Q3 2026 after the market close on Oct. 26, 2026 and hold its earnings call on Oct. 27.
- 2026-09-30 Implied Volatility Surging for Universal Health Services Stock Options Investors need to pay close attention to UHS stock based on the movements in the options market lately.
- 2026-09-28 Universal Health Services (NYSE:UHS) versus Exagen (NASDAQ:XGN) Financial Analysis Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends. Institutional and Insider Ownership 86.0% of Universal Health
- 2026-09-26 Universal Health Services, Inc. (NYSE:UHS) Stock Now Rated “Hold” by Sell-Side Analysts Shares of Universal Health Services, Inc. (NYSE: UHS - Get Free Report) have been given a consensus recommendation of "Hold" by the eighteen research firms that are presently covering the company, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company.
- 2026-09-24 State Street Corp Sells 476,776 Shares of Universal Health Services, Inc. $UHS State Street Corp cut its stake in shares of Universal Health Services, Inc. (NYSE: UHS) by 18.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,102,613 shares of the health services provider''s stock after selling 476,776 shares during the period.
- 2026-09-17 Sequoia Financial Advisors LLC Increases Holdings in Universal Health Services, Inc. $UHS Sequoia Financial Advisors LLC raised its holdings in Universal Health Services, Inc. (NYSE: UHS) by 83.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,026 shares of the health services provider''s stock after buying an additional 3,200 shares during the quarter.
- 2026-09-17 Engineers Gate Manager LP Acquires 9,511 Shares of Universal Health Services, Inc. $UHS Engineers Gate Manager LP grew its holdings in shares of Universal Health Services, Inc. (NYSE: UHS) by 840.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,643 shares of the health services provider''s stock after acquiring an additional
- 2026-09-15 Universal Health Services, Inc. (UHS) Presents at 2026 Global Healthcare Conference Transcript Universal Health Services, Inc. (UHS) Presents at 2026 Global Healthcare Conference Transcript
- 2026-09-14 Universal Health Services, Inc. (UHS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Universal Health Services, Inc. (UHS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-08 Universal Health Services, Inc. (UHS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Universal Health Services, Inc. (UHS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript